The pro-inflammatory properties of interleukin-8 (IL-8) suggest a major role of this peptide in inflammatory processes of skin and other organs. Both biochemical and immunohistochemical studies from our group have demonstrated IL-8 peptide within psoriatic scales and epidermis. So far, however, the relevance of circulating IL-8 and its relation to locally produced IL-8 in this disease remain unclear. Serum IL-8 levels of psoriatic patients were determined in sandwich-ELISA prior to therapy as well as during therapy. Using either the assay from our laboratory or three commercial ELISAs, no correlation was found between serum IL-8 levels and disease severity at any stage of the disease. Similarly, epidermal IL-8-immunoreactivity was monitored immunohistochemically in sequential biopsies from individual psoriatic lesions as they resolved during the course of therapy. Initially, decreased epidermal IL-8 immunoreactivity shifted to a homogeneous staining comparable to normal or non-diseased skin as lesions resolved under treatment. These results indicate a role of IL-8 at local level in psoriatic skin. In contrast to hyperinflammatory dermatoses like sepsis, where increased serum IL-8 levels are found, in psoriasis either circulating IL-8 is absent or potent mechanisms are operative effectively binding and/or inactivating IL-8 as it enters circulation. Key words: chemokine; ELISA; immunohistochemistry; psoriatic skin; serum.

MATERIAL AND METHODS
The study has been approved by the local ethics committee. Patients agreed to participate by written consent after appropriate consulting.

Serum samples from psoriatic patients
Prior to therapy, as well as once every week under therapy, serum samples were obtained from 63 psoriatic patients. Simultaneously, disease severity was monitored by assessing the psoriasis area and severity index (PASI) (12). Major laboratory parameters, including blood sedimentation rate, liver enzymes and blood cell counts, were evaluated at the same time points.

Immunoaassays for serum IL-8 concentrations
Serum samples from all patients were tested in a sandwich ELISA using monoclonal anti-IL-8-antibodies (moAb) as described previously (13). moAb 52E8 served as coating and moAb 14E5 coupled to biotin as detecting antibody. Colour reaction was induced using the avidin-biotin-peroxidase-complex method with o-phenylenediamine as colour reagent. Serial dilutions of recombinant IL-8 (Peprotech, London) were always included and relevant IL-8 levels read from the standard curve. The ELISA was shown to be specific for IL-8 with a detection limit of 50 pg/ml. Similarly, serum samples taken before initiation of therapy were tested in three different commercial IL-8-ELISAs according to manufacturers’ instructions (R&D, Minneapolis, USA; Bender, Vienna; Amersham, Germany).

Skin biopsies from patients with psoriasis vulgaris
Among 10 patients participating in this part of the study, five presented with the clinical aspect of guttate psoriasis; the other five showed plaque type psoriasis. Biopsies were obtained on the day of admission to hospital prior to treatment and thereafter sequentially at 10-day intervals. Altogether, 3–6 biopsies were taken from each patient during the time of hospital treatment. Therapy consisted of topical steroids under occlusion or dithranol in conjunction with PUVA or UVB treatment. Four-mm punch biopsies were taken from the border of the same psoriatic lesions for each patient in a standard manner after local anaesthesia (Scandicain 1%), snap-frozen and stored in liquid nitrogen until further processing.

Immunohistochemical examination of IL-8 expression
Between 4 and 6 µm cryostat sections of the sequential biopsies were processed as described earlier (10, 14). Briefly, after fixation with acetone for 10 min, moAb 52E8 was added as primary antibody. Colour reaction was achieved using the avidin-biotin-peroxidase method with a goat-anti-mouse IgG antibody coupled to biotin, avidin-biotin-peroxidase complex (ABC-kit, Vector Labs., Burlingame, England) and diaminobenzidine as colour reagent. moAb 52E8 has been produced and extensively characterized as described earlier (10, 15, 16). For immunohistochemical studies, culture supernatants from the respective clone were used at appropriate dilutions tested in advance. Negative controls consisted of isotype-matched irrelevant antibodies or substitution of primary antibody by buffer. Immunohistochemical results were evaluated by two independent investigators in respect to IL-8-immunoreactivity related to parakeratosis, acanthosis and dermal as well as epidermal inflammatory infiltrate. Grading was from 0 (negative) to +++++ (intense).
RESULTS

Serum IL-8 levels

Serum IL-8 levels as detected in the ELISA established in our laboratory (13) ranged from 2 to 16 ng/ml. They did not correlate to the PASI prior to treatment, which varied from a score between 2 and 42 (Fig. 1). Furthermore, no correlation could be found to serum parameters like blood sedimentation rate, blood cell count or hepatic enzymes (results not shown). During the course of therapy with clinical resolution of psoriatic lesions, individual IL-8 levels did not correlate to clinical improvement. Instead, they were found static within most patients, with both a slight decrease and increase in a few others (results not shown). Similarly, differences among therapeutic regimens used in this study could not be detected (results not shown).

In addition to our own assay, serum samples were tested in three commercially available IL-8 ELISAs. Representative results on a set of 18 different serum samples are shown in Fig. 2 for all four assays used in this study. Widely diverging IL-8 levels could be found within the same serum samples. However, in not one of the ELISAs used could a correlation with PASI be found.

Immunohistochemical studies

In immunohistology using moAb 52E8, one patient each with either plaque type and guttate psoriasis demonstrated homogeneous staining of suprabasal keratinocytes in all sequential biopsies. All other patients showed reduced epidermal staining in the first biopsy taken at the time of admission to the hospital without prior treatment. Decrease of staining prior to treatment consisted in a loss of immunoreactivity in the lower keratinocyte layers, the extent of which varied from patient to patient (Fig. 3A).

Upon resolution of skin lesions during the course of therapy, a homogeneous staining of all suprabasal keratinocytes was gradually regained parallel to a decrease of acanthosis and inflammatory infiltration (Fig. 3A – D). At the time of dismissal from hospital, skin lesions had vanished for all but residual erythema in some cases. At that time, immunohistochemical staining for IL-8 was comparable to that of normal or non-diseased psoriatic skin. In respect of the different therapy regimens used, no differences in immunohistochemical staining pattern nor time-course could be seen.

At all clinical stages, epidermal IL-8 immunoreactivity was prominent. In the dermis, staining was occasionally seen within endothelial cells, dendritic and mononuclear cells and could be related neither to the degree of inflammatory infiltration nor clinical state. It in fact varied between different patients as well as within several biopsies taken from single patients. Cells of the acrosyringium and hair follicle always remained positive in sharp contrast to surrounding keratinocytes.

DISCUSSION

IL-8 has been detected in a number of inflammatory disorders (2) like rheumatoid arthritis (17), sepsis (18), inflammatory lung diseases (19) as well as various dermatological disorders (2, 4). Our group has presented biochemical data on the involvement of the peptide in psoriasis vulgaris by demonstrating biologically active IL-8 in psoriatic scales (3 – 5). Furthermore, in immunohistochemical studies, psoriatic skin (10) as well as contact eczema and atopic dermatitis (14) were examined. The pattern of epidermal immunoreactivity correlated to the inflammatory state of the tissue with homogeneous epidermal staining in mildly inflamed tissue, whereas focal decrease or even total absence of epidermal staining was present in highly inflamed tissue. In those studies, single biopsies from different patients were taken at the time of admission to the hospital prior to any treatment and probably represented different stages of the disease (10).

In the present study, sequential biopsies from individual psoriatic lesions were examined following various treatment modalities. A gradual shift of IL-8 epidermal immunoreactivity was found which can be related to the duration of treatment and clinical improvement. There was no obvious influence of the type of antipsoriatic therapy. In addition to external steroids, dithranol and UV treatment as used in this study, similar results were found using topical calcitriol (20). In another study, the amount of IL-8 peptide in psoriatic lesions was found to decrease during calcipotriene treatment (21). These findings demonstrate that epidermal IL-8 immunoreactivity is in a dynamic state and further substantiate our previous data. Whereas decreased or even absent IL-8 immunoreactivity was found in skin specimens at the beginning of treatment, homogeneous epidermal staining was found upon clinical resolution of skin lesions. At that stage, immunoreactivity was comparable to normal or non-diseased skin (10).

Partly controversial results have been raised in studies of psoriatic tissue using immunohistochemical as well as probe-based methods. Whereas in one study IL-8 was undetectable...
within normal epidermis (7), others were able to demonstrate a shift of IL-8 immunoreactivity from all epidermal layers as seen in normal skin towards upper layers in inflamed tissue (10, 11). Using probe-based methods, IL-8 mRNA has been found in suprabasal (9) or focally in upper cell layers between squirting papillae (8).

Similar to our results on IL-8, two other chemokines of the CXC family, MGSA/groα (22) and IP-10 (23) could be demonstrated immunohistochemically in normal skin with a characteristic shift of immunoreactivity in psoriasis. Such results, as well as in vitro data of mitogenic activity on keratinocytes (24), indicate that these chemokines as well as IL-8 play a role in normal epidermal growth and differentiation (4) and in inflammation.

In contrast to immunohistochemical results on local IL-8 expression, serum IL-8 levels did not correlate with severity of psoriasis and state of the disease as reflected by PASI. No correlation was found in any of four different IL-8 ELISA formats. In studies by various authors on IL-8 serum or plasma levels, a wide range of immunoassays with different monoclonal and polyclonal antibodies were used (2, 25). Differential reactivity of these antibodies (26) with IL-8 in dimerized form or

Fig. 3. Interleukin-8 immunoreactivity after staining with anti-IL-8 moab 52E8. Sequential biopsies from a patient with guttate psoriasis taken on the day of admission to hospital (A, 100×), and upon treatment with topical steroids and UVB-irradiation after 10 days (B, 100×), 25 days (C, 400×), 35 days (D, 200×) on discharge from hospital.
complexed with so-called natural anti-IL-8 antibody as described by Sylvester et al. (27) could explain diverging results. Accordingly, standardization was found to be a major problem in cytokine immunoassays, including those for IL-8, and different results were raised when studying the same samples in different assays (26–29).

Apart from these technical problems in cytokine detection, a number of mechanisms have recently been described which can bind and inactivate both circulating IL-8 and locally produced peptide. A promiscuous chemokine receptor has been found on the glycoprotein carrying the Duffy blood group antigen (30). It is expressed most abundantly on erythrocytes, but can be demonstrated on postcapillary venules as well (31). Most chemokines are bound with similar affinity, in contrast to other chemokine receptors which are much more discriminative (1, 2, 30). Furthermore, IL-8 is known to preferentially bind to heparin (2, 32). Consequently, glycosaminoglycans which are abundantly present in dermal connective tissue including skin vasculature are able to bind locally produced IL-8 (32, 33) and may thus prevent it from entering the circulation.

Furthermore, as mentioned above, so-called natural anti-IL-8 antibodies have been demonstrated in serum of healthy individuals (27). Similar to antibodies against IL-1, IL-6 and TNFα (34), these are assumed to both inactivate and store cytokines for ample response under inflammatory conditions. All these mechanisms represent potentially important control mechanisms of IL-8 which are produced either locally or systemically.

Recently, IL-8 levels were found to correlate to disease severity and prognosis in diseases like sepsis (2, 18). Massive production of IL-8 by circulating cells in these hyperinflammatory diseases is thought to overcome the inhibitory mechanisms described above (18). Regarding the size of the skin organ with abundant dermal tissue and vasculature, local binding mechanisms may be especially important in inflammatory diseases afflicting this organ. In fact, we could find similar results of low IL-8 levels and lacking correlation to disease severity in atopic eczema (own unpublished results).

Altogether, our study enforces earlier data that IL-8 is produced at local level to focus and amplify inflammatory responses. Evidently, however, these local processes are not reflected by the systemic IL-8 level even in cases of severely involved psoriatic skin. Consequently, serum IL-8 levels do not provide diagnostic or prognostic criteria in psoriasis.

ACKNOWLEDGMENT

This study was supported in part by Deutsche Forschungsgemeinschaft grants Sti 95/2-3 and Chr 38/7-2 (Clinical Research Group). We greatly appreciate the excellent technical work of Anke Rose and Nicole Plate.

REFERENCES

24. Tuschil A, Lam C, Haslberger A, Lindley J. Interleukin-8 stimu-


